Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986419
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BMS-986419 (also known as EVT-8683 and EOAI-4018683) is an orally administered small molecule drug in development for the treatment of neurodegenerative disorders, specifically Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It acts as an activator of eukaryotic translation initiation factor 2B (eIF2B), a key regulator in the integrated stress response pathway. By stimulating eIF2B, BMS-986419 aims to restore protein synthesis impaired during cellular stress, which is implicated in neurodegeneration. The drug was originally discovered by Evotec SE and is being developed by Bristol Myers Squibb in collaboration with Evotec SE. As of early 2025, it is undergoing Phase I clinical trials for ALS and other neurodegenerative disorders[1][2][7].
- Brand names
- Comtifator
- Other names
- eIF2b activatoreIF-2b activatoreIF 2b activator
02
Targets
eIF2B (Eukaryotic translation initiation factor 2B)
Beyond the preview
Go deeper on BMS-986419.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986419.